Interferons, immunity and cancer immunoediting

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Nature reviews. Immunology

• Publication date

  2006-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nri1961PMID 17063185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.

  2007cited by this paper
• IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice

  2006cited by this paper
• Prognostic significance of autoimmunity during treatment of melanoma with interferon.

  2006cited by this paper
• Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant

  2006cited by this paper
• Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.

  2006cited by this paper
• IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors1

  2006cited by this paper
• Paradoxical roles of the immune system during cancer development

  2006cited by this paper
• Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis

  2006cited by this paper
• IL-23 promotes tumour incidence and growth

  2006cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Blocking Monoclonal Antibodies Specific for Mouse IFN-α/β Receptor Subunit 1 (IFNAR-1) from Mice Immunized byIn Vivo Hydrodynamic Transfection

  2006cited by this paper
• The DNA damage response arouses the immune system.

  2006cited by this paper
• IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response.

  2005cited by this paper
• Transcriptionally active Statl is required for the antiproliferative effects of both interferon a and interferon

  2005cited by this paper
• Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance

  2005cited by this paper
• Plasmacytoid dendritic cells

  2005cited by this paper
• NKG2D function protects the host from tumor initiation

  2005cited by this paper
• Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1

  2005cited by this paper
• Mechanisms of type-I- and type-II-interferon-mediated signalling

  2005cited by this paper
• IFN-γ Controls the Generation/Activation of CD4+CD25+ Regulatory T Cells in Antitumor Immune Response1

  2005cited by this paper
• Interleukin 12 and tumor necrosis factor a are costimulators of interferon y production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist

  2005cited by this paper
• The Yin and Yang of type I interferon activity in bacterial infection

  2005cited by this paper
• A critical function for type I interferons in cancer immunoediting

  2005cited by this paper
• Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.

  2005cited by this paper
• IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression.

  2005cited by this paper
• STAT5 contributes to interferon resistance of melanoma cells.

  2005cited by this paper
• Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma.

  2004cited by this paper
• Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells

  2004cited by this paper
• Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma.

  2004cited by this paper
• Interferons, interferon‐like cytokines, and their receptors

  2004cited by this paper
• Issues in T‐helper 1 development – resolved and unresolved

  2004cited by this paper
• The immunobiology of cancer immunosurveillance and immunoediting.

  2004cited by this paper
• PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity

  2004cited by this paper
• The three Es of cancer immunoediting.

  2004cited by this paper
• The role of type I interferons in non‐viral infections

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

  2003cited by this paper
• CHAPTER 24 – Interferon-γ

  2003cited by this paper
• Implications for RNase L in prostate cancer biology.

  2003cited by this paper
• Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer

  2003cited by this paper
• The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

  2003cited by this paper
• α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

  2003cited by this paper
• The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin Cancer

  2003cited by this paper
• γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity

  2003cited by this paper
• CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses

  2003cited by this paper
• The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse

  2003cited by this paper
• The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.

  2003cited by this paper
• Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence

  2003cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases

  2002cited by this paper
• Interferon‐α as an immunotherapeutic protein

  2002cited by this paper
• Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development

  2002cited by this paper
• Rules for making human tumor cells.

  2002cited by this paper
• Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice.

  2002cited by this paper
• Interferon-alpha as an immunotherapeutic protein.

  2002cited by this paper
• Interferon-alpha in tumor immunity and immunotherapy.

  2002cited by this paper
• The roles of IFN gamma in protection against tumor development and cancer immunoediting.

  2002cited by this paper
• A Critical Role for Natural Killer T Cells in Immunosurveillance of Methylcholanthrene-induced Sarcomas

  2002cited by this paper
• Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1

  2002cited by this paper
• The roles of IFNγ in protection against tumor development and cancer immunoediting

  2002cited by this paper
• Enhanced Tumor Development in Mice Lacking a Functional Type I Interferon Receptor

  2002cited by this paper
• Clinical translation of angiogenesis inhibitors

  2002cited by this paper
• Germline mutations in the ribonuclease L gene in families showing linkage with HPC1

  2002cited by this paper
• Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ

  2002cited by this paper
• Regulation of Cutaneous Malignancy by γδ T Cells

  2001cited by this paper
• Regulation of cutaneous malignancy by gammadelta T cells.

  2001cited by this paper
• p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma.

  2001cited by this paper
• NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

  2001cited by this paper
• IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

  2001cited by this paper
• IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma.

  2001cited by this paper
• Inhibition of Cellular Responsiveness to Interferon-y (IFNy) Induced by Overexpression of Inactive Forms of the IFNy Receptor*

  2001cited by this paper
• Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

  2001cited by this paper
• IFN-γ-Dependent Inhibition of Tumor Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor Responsiveness to IFN-γ1

  2001cited by this paper
• Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-γ

  2001cited by this paper
• Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function.

  2000cited by this paper
• p 53-Independent Upregulation of KILLER / DR 5 TRAIL Receptor Expression by Glucocorticoids and Interferon-g

  2000cited by this paper
• Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

  2000cited by this paper
• Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells

  2000cited by this paper
• The HLA crossroad in tumor immunology.

  2000cited by this paper
• Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma

  2000cited by this paper
• Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

  2000cited by this paper
• Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice1

  2000cited by this paper
• Partial impairment of cytokine responses in Tyk2-deficient mice.

  2000cited by this paper
• Antigen-processing machinery breakdown and tumor growth.

  2000cited by this paper
• CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ

  1999cited by this paper
• Induction of interferon‐γ production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation

  1999cited by this paper
• SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality.

  1999cited by this paper
• SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine

  1999cited by this paper
• Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis

  1999cited by this paper
• CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.

  1999cited by this paper
• Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.

  1999cited by this paper
• Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation.

  1999cited by this paper
• Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.

  1999cited by this paper
• SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine.

  1999cited by this paper
• Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

  1998cited by this paper
• How cells respond to interferons.

  1998cited by this paper
• Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

  1998cited by this paper
• Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

  1998cited by this paper
• Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.

  1998cited by this paper
• IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression.

  1998cited by this paper

• Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas

  2026cites this paper
• Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity

  2026cites this paper
• Magnesium-Enhanced Magnetic Hyperthermia for Triggering Vaccine-Like Antitumor Immunotherapy.

  2026cites this paper
• Fasting-mimicking diet induces IFNβ secretion in tumor-associated macrophages via NRF1-mediated ubiquitin-dependent proteolysis of Trex1.

  2026cites this paper
• S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity

  2026cites this paper
• Tumor cell villages define the co-dependency of tumor and microenvironment in liver cancer

  2026cites this paper
• The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer

  2026cites this paper
• Arachidonic acid analog AACOCF3 suppresses cPLA2-negative NSCLC cell proliferation by targeting SSRP1 to activate the IFNα/β pathway.

  2026cites this paper
• A stochastic agent-based model for simulating tumor-immune dynamics and evaluating therapeutic strategies

  2025cites this paper
• The recurrence or metastasis related gene predicts the prognosis of extremity and trunk soft tissue sarcoma

  2025cites this paper
• Predicting treatment-free remission in chronic myeloid leukemia patients using an integrated model of tumor-immune dynamics

  2025cites this paper
• Deletion of the GntR8 transcriptional regulator impairs Brucella abortus intracellular survival and virulence by modulating stress response genes

  2025cites this paper
• ST6GAL1-mediated sialylation inhibits the antitumor immune response in colorectal cancer

  2025cites this paper
• ISG20: The multifaceted ‘molecular star’ in cancer research (Review)

  2025cites this paper
• Unconventional Immunotherapies in Cancer: Opportunities and Challenges

  2025cites this paper
• Innate immunity in tumour immunoediting and immunosurveillance

  2025cites this paper
• The Immune-Modulatory Function of Megakaryocytes in the Hematopoietic Niche of Myeloproliferative Neoplasms

  2025cites this paper
• Prognostic significance of preoperative Naples prognostic score for disease-free and overall survival in oral cavity squamous cell carcinoma post-surgery

  2025cites this paper
• Cationic nanogel-based nasal therapeutic HPV vaccine prevents the development of cervical cancer.

  2025cites this paper
• Heterogeneity of the tumor immune cell microenvironment revealed by single-cell sequencing in head and neck cancer.

  2025cites this paper
• Advances in cancer immunotherapy: historical perspectives, current developments, and future directions

  2025cites this paper
• The Role of Nuclear Factor-κB in Cancer Immunity and Immunoediting

  2025cites this paper
• Carbonic Anhydrase Targeting Polymer with Enhanced Intracellular Protein Delivery and Tumor Penetration for Cancer Therapy.

  2025cites this paper
• Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies

  2025cites this paper
• Intron retention regulates STAT2 function and predicts immunotherapy response in lung cancer

  2025cites this paper
• Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities

  2025cites this paper
• Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics

  2025cites this paper
• Mapping CD4+ T Cell Landscapes in Glioblastoma Reveals Effectors and Bystanders

  2025cites this paper
• The difference in tumor immune microenvironment and IFN-γ response between solid and non-solid adenocarcinoma

  2025cites this paper
• Exploratory Pharmacokinetic Study of Pegylated Interferon Alfa-2b Aerosolized Inhalation Administration.

  2025cites this paper
• Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression

  2025cites this paper
• Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy

  2025cites this paper
• Tumor cell villages define the co-dependency of tumor and microenvironment in liver cancer

  2025cites this paper
• The anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells

  2025cites this paper
• IRF1 is a context-dependent homeostatic gatekeeper of basal immunity and antiviral readiness

  2025cites this paper
• Down-Regulation of HLA-C Expression on Melanocytes May Contribute to the Therapeutic Efficacy of UVB Phototherapy in Psoriasis

  2025cites this paper
• Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances

  2025cites this paper
• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Targeting leukocyte immunoglobulin‑like receptor B2 in the tumor microenvironment: A new treatment prospect for solid tumors (Review)

  2025cites this paper
• A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy

  2025cites this paper
• Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial

  2025cites this paper
• Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies

  2025cites this paper
• Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells.

  2025cites this paper
• Myeloid cell-targeted lipid nanoparticles for B cell lymphoma immunotherapy

  2025cites this paper
• Biomineralized Engineered Bacterial Outer Membrane Vesicles as cGAS-STING Nanoagonists Synergize with Lactate Metabolism Modulation to Potentiate Immunotherapy.

  2025cites this paper
• Cytokine expression of soft tissue cells cultured with titanium discs and their respective supernatants in vitro

  2025cites this paper
• Improving the Accumulation and Solubility of Human Interferon-γ (hIFN-γ) in Escherichia coli: A Fusion Protein-Based Method and Network Pharmacology Analysis

  2025cites this paper
• Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival.

  2025cites this paper
• OASL enhances mRNA translation and reprograms lipid metabolism to promote cancer progression.

  2025cites this paper
• Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma

  2025cites this paper
• Unveiling Diagnostic Significance: Exploring miR-21, IL-12, and INF-Y in Various Breast Cancer Stages and Grades

  2025cites this paper
• Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation

  2025cites this paper
• Metabolic reprogramming and interventions in angiogenesis

  2024cites this paper
• Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells

  2024cites this paper
• Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?

  2024cites this paper
• Non-viral vector-based genome editing for cancer immunotherapy.

  2024cites this paper
• Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses

  2024cites this paper
• Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor cells

  2024cites this paper
• GPR124 promotes trophoblast proliferation, migration, and invasion and inhibits trophoblast cell apoptosis and inflammation via JNK and P38 MAPK pathways

  2024cites this paper
• The prognostic value of sialylation-related long non-coding RNAs in lung adenocarcinoma

  2024cites this paper
• Prognostic model and ceRNA network of m7G- and radiosensitivity-related genes in hepatocellular carcinoma

  2024cites this paper
• Therapeutic efficacy of a novel self-assembled immunostimulatory siRNA combining apoptosis promotion with RIG-I activation in gliomas

  2024cites this paper
• Platinum-based neoadjuvant chemotherapy upregulates STING/IFN pathway expression and promotes TILs infiltration in NSCLC

  2024cites this paper
• Astragalus polysaccharide ameliorates CD8+ T cell dysfunction through STAT3/Gal-3/LAG3 pathway in inflammation-induced colorectal cancer.

  2024cites this paper
• Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages

  2024cites this paper
• Essential contribution of the JAK/STAT pathway to carcinogenesis, lytic infection of herpesviruses and pathogenesis of COVID‑19 (Review)

  2024cites this paper
• Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy

  2024cites this paper
• Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma

  2024cites this paper
• Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors

  2024cites this paper
• Enhanced Antiglioma Effect by a Vitamin D3-Inserted Lipid Hybrid Neutrophil Membrane Biomimetic Multimodal Nanoplatform.

  2024cites this paper
• A STAT3–STING–IFN axis controls the metastatic spread of small cell lung cancer

  2024cites this paper
• Identification of prognostic models for glycosylation-related subtypes and tumor microenvironment infiltration characteristics in clear cell renal cell cancer

  2024cites this paper
• Schistosoma mansoni soluble egg antigen suppresses colorectal cancer growth in vitro and in vivo.

  2024cites this paper
• The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer

  2024cites this paper
• The curious case of interferon-1 signaling in cancer.

  2024cites this paper
• Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo.

  2024cites this paper
• Proteomic profiling of oral squamous cell carcinoma tissues reveals altered immune-related proteins: implications for personalized therapy

  2024cites this paper
• Long-term prognosis and treatment modalities of hepatic epithelioid hemangioendothelioma: a retrospective study of 228 patients

  2024cites this paper
• Predicting treatment-free remission outcomes in Chronic Myeloid Leukemia patients using an integrated model of tumor-immune dynamics

  2024cites this paper
• Tumor growth suppression in adoptive T cell therapy via IFN-γ targeting of tumor vascular endothelial cells

  2024cites this paper
• Co-evolution of glioma and immune microenvironment

  2024cites this paper
• Modulation of the malignant behavior of tongue squamous cell carcinoma cells by matrix metallopeptidase 25 through the NF-κB pathway.

  2024cites this paper
• Promiscuous Janus kinase binding to cytokine receptors modulates signaling efficiencies and contributes to cytokine pleiotropy.

  2024cites this paper
• Genomic instability as a driver and suppressor of anti-tumor immunity

  2024cites this paper
• Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients’ blood

  2024cites this paper
• Site-specific O-GlcNAcylation of progesterone receptor (PR) supports PR attenuation of interferon stimulated genes (ISGs) and tumor growth in breast cancer

  2024cites this paper
• CD91 and its ligand gp96 confer cross-priming capabilities to multiple APCs during immune responses to nascent, emerging tumors.

  2024cites this paper
• Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy

  2024cites this paper
• Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift

  2024cites this paper
• Human autoantibodies neutralizing type I IFNs: From 1981 to 2023

  2024cites this paper
• Novel prognostic model of complement and coagulation cascade-related genes correlates with immune environment and drug sensitivity in hepatocellular carcinoma

  2024cites this paper
• Interferon-β Overexpression in Adipose Tissue-Derived Stem Cells Induces HepG2 and Macrophage Cell Death in Liver Tumor Organoids via Induction of TNF-Related Apoptosis-Inducing Ligand Expression

  2024cites this paper
• Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma

  2024cites this paper
• Interferon gamma induces higher neutrophil extracellular traps leading to tumor-killing activity in microsatellite stable colorectal cancer.

  2024cites this paper
• Microbiota-associated mechanisms in colorectal cancer.

  2024cites this paper
• Atlas of the plasma proteome in health and disease in 53,026 adults.

  2024cites this paper
• FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population

  2024cites this paper
• Differential abundance of DNA damage sensors and innate immune signaling proteins in INPP4B negative TNBC classified by immunotype.

  2024cites this paper
• Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy

  2024cites this paper
• Cell–cell communication: new insights and clinical implications

  2024cites this paper